1. Short title This Act may be cited as the COVID–19 in Immigration Detention Data Transparency Act . 2. Definitions In this Act: (1) CBP detention facility The term CBP detention facility means any facility used by U.S. Customs and Border Protection to detain noncitizens. (2) CDC director The term CDC Director means the Director of the Centers for Disease Control and Prevention. (3) Contract detention facility The term contract detention facility means any facility used for the detention of noncitizens that is operated by a government agency or a private entity that has contracted with U.S. Immigration and Customs Enforcement, U.S. Customs and Border Protection, or the Office of Refugee Resettlement to provide such detention services, including service processing centers, juvenile detention facilities, family residential centers, facilities holding noncitizens awaiting removal, and similar facilities operating under an intergovernmental service agreement with any of such Federal agencies, including intergovernmental agreements with the United States Marshals Service. (4) COVID– 19 The term COVID–19 means the 2019 novel coronavirus disease caused by the SARS–CoV–2 virus. (5) COVID–19 diagnostic test The term COVID–19 diagnostic test means a test— (A) that is an in vitro diagnostic product (as defined in section 809.3 of title 21, Code of Federal Regulations) for the detection of SARS–CoV–2; and (B) the administration of which— (i) is approved, cleared, or authorized under section 510(k), 513, 515, or 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360(k) , 360c, 360e, 360bbb–3); (ii) the developer has requested, or intends to request, emergency use authorization under section 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3 ), unless and until the emergency use authorization request under such section 564 has been denied or the developer of such test does not submit a request under such section within a reasonable timeframe